publication date: May. 23, 2014

Guest Editorial

A Near-Term Solution: NCI And COG Agree on Plan to Maintain Enrollment
By Peter C. Adamson


As funding issues surrounding the NCI’s new National Clinical Trials Network (NCTN) have been a prominent topic of recent news and discussions, to help inform the cancer research community, we are taking this opportunity to share data regarding NCTN funding to the Children’s Oncology Group (COG). 

The COG was the recipient of three NCTN grants: a Network Operations Center grant, a Network Statistics & Data Center grant, and an Integrated Translational Science Center (ITSC) grant. Similar to other members of the NCTN, the funding support and restrictions on utilization of that support provided under the Network Operations Center grant created an unparalleled fiscal challenge for the COG.

As originally issued, the Notice of Award (NOA) for this grant resulted in a $6.9M budget gap relative to FY13, a budget gap that would have resulted in closure of a major component of ongoing clinical trials and delayed or prevented the activation of approved new studies. 

However, over the past several weeks, we have worked closely with NCI-CTEP leadership to develop a series of solutions to narrow this budget gap. A path forward has been defined that in the near term should allow COG to continue enrollment to all studies within its current clinical trial portfolio. 

Here we provide details of the budget cuts to the COG and the agreed-upon bridging strategy geared towards lessening the negative impact these cuts will have for childhood cancer research and children with cancer. 

Childhood Cancer Research Funding Landscape

Continue reading 40-21 A Near-Term Solution: NCI & COG Agree on Plan to Maintain Enrollment

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.